- AbbVie Presents Data Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
- Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
- Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells
- ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
- Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
- Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
- Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
- Blincyto (Blinatumomab) Added to Consolidation Chemotherapy Significantly Improves Survival in Adult Patients With Measurable Residual Disease-Negative B-Lineage Acute Lymphoblastic Leukemia (B-ALL)
- Body Of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta CAR T-Cell Therapy For Patients With Relapsed Or Refractory Large B-Cell Lymphoma
- Bristol Myers Squibb Announces First Disclosures and New Data including alnuctamab, Abecma, GPRC5D CAR T (BMS-986393/CC-95266) and novel oral CELMoDTM agents mezigdomide and iberdomide
- Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial
- Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
- Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma
- Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas
- Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
- Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
- Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
- Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF)
- Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
- Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial
- Magenta Therapeutics Presents Positive MGTA-117 Clinical Data
- Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML
- MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis
- MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity
- Nektar Announces Poster Presentations for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies and First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
- New Analyses Of Kite’s Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival And Durability Of Response
- ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine
- Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
- Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma debut
- Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
- Roche Presents New Data Demonstrating The Potential Benefit Of Glofitamab And Lunsumio As Fixed-Duration, Off-The-Shelf Treatment Options For Lymphoma
- Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
- Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis
- Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
- Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations
- Three-Year Follow-Up Analysis Of Kite’s Yescarta® CAR T-Cell Therapy (ZUMA-5 Trial) – 52% Of Patients With Indolent Lymphomas Continued To Have Ongoing Responses At A Median Follow-Up Of 40.5 Months
- Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study
Menu
